A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

Summary

This single arm study will evaluate the efficacy and safety of MabThera monotherapy in patients with refractory, relapsing or chronic idiopathic thrombocytopenic purpura (ITP). Patients will receive infusions of MabThera 1000mg i.v. on days 1 and 15. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Timeline

Start

2007-05

Primary completion

2011-08

Completion

2011-08

Drugs

Indications